TABLE 4.
H. pylori isolate MIC values and drug resistance-associated mutations for levofloxacin, tetracycline, and metronidazolea
| Isolate IDb | Cancer risk group | LEV | gyrA (LEV) | TET | 16s rRNA (TET) | MTZ | rdxA (MTZ) | frxA (MTZ) |
|---|---|---|---|---|---|---|---|---|
| MT5110 | LGCR | 8–32 | N87I | S | 16–64 | >217 ELONGATED | ||
| MT5118* | LGCR | 8 | N87K | S | 32–64 | |||
| MT5125* | LGCR | 32 | N87I | S | 32–64 | M1V | 73 STOP | |
| MT5127 | LGCR | 4–8 | D91Y | S | 64–128 | 38 STOP | ||
| MT5156* | LGCR | S | N87T | S | 64–128 | 10 STOP | 73 STOP | |
| MT5165* | LGCR | S | S | 16–32 | 86 STOP | 108 STOP | ||
| MT5175* | LGCR | S | S | 16–32 | 145 STOP | |||
| MT5178 | LGCR | S | S | 32–64 | 73 STOP | |||
| MT5179 | LGCR | 32 | N87I | S | 64–128 | 122 STOP | 73 STOP | |
| MT5101* | LGCR | S | S | 64 | M1V | 38 STOP | ||
| MT5105* | LGCR | 8–32 | N87I | S | 32–64 | 73 STOP | ||
| MT5106* | LGCR | S | S | 64 | 38 STOP | |||
| MT5107 | LGCR | S | S | 32–64 | 49 STOP | 38 STOP | ||
| MT5111* | LGCR | S | N87T | S | 64–128 | 82 STOP | 73 STOP | |
| MT5113 | LGCR | S | N87T | S | 64 | 49 STOP | ||
| MT5114* | LGCR | 16 | N87I | S | 64 | 73 STOP | 73 STOP | |
| MT5116* | LGCR | S | S | 64 | 145 STOP | 38 STOP | ||
| MT5117 | LGCR | S | N87T | S | 64–128 | 73 STOP | ||
| MT5119* | LGCR | S | S | 32–64 | 73 STOP | |||
| MT5120* | LGCR | S | S | 64–128 | 167 STOP | |||
| MT5124* | LGCR | 16–32 | N87I | S | 128 | 73 STOP | ||
| MT5126 | LGCR | S | S | 32–64 | 64 STOP | 129 STOP | ||
| MT5131* | LGCR | S | N87T | S | 64 | 26 STOP | 73 STOP | |
| MT5135* | LGCR | S | N87T | S | 32–64 | 73 STOP | ||
| MT5136* | LGCR | S | N87T | S | 64 | 26 STOP | 73 STOP | |
| MT5139 | LGCR | 4 | N87T, D91Y | S | 16–64 | 32 STOP | ||
| MT5155 | LGCR | S | S | 32 | 67 STOP | |||
| MT5176* | LGCR | S | S | 16–64 | ||||
| PZ5004* | LGCR | S | S | 32–64 | 101 STOP | 73 STOP | ||
| PZ5024 | LGCR | S | N87T | S | 32–64 | 211 ELONGATED | 73 STOP | |
| PZ5026* | LGCR | S | N87T | S | 64–128 | 129 STOP | 38 STOP | |
| MT2139 | HGCR | S | S | 64 | 148 STOP | |||
| MT2141* | HGCR | S | S | 64 | 209 STOP | 38 STOP | ||
| MT2158* | HGCR | S | N87T | S | 64–128 | 49 STOP | 73 STOP | |
| MT2164* | HGCR | S | S | 32–64 | 110 STOP | |||
| MT2143 | HGCR | S | S | >32 | 49 STOP | 38 STOP | ||
| MT2171* | HGCR | S | S | S | ||||
| MT2174* | HGCR | S | S | 64–128 | ||||
| MT2102 | HGCR | S | S | S | 38 STOP | |||
| MT2106 | HGCR | S | N87T | S | 32–64 | 148 STOP | ||
| MT2108 | HGCR | S | S | S | 38 STOP | |||
| MT2112 | HGCR | S | S | 16–32 | 10 STOP | |||
| MT2114 | HGCR | S | S | 16–32 | 215 ELONGATED | |||
| MT2115 | HGCR | S | S | 8 | 38 STOP | |||
| MT2118 | HGCR | S | S | 32 | 58 STOP | 73 STOP | ||
| MT2120* | HGCR | S | S | 64 | 157 STOP | 38 STOP | ||
| MT2122* | HGCR | S | S | 32–64 | 38 STOP | |||
| MT2124 | HGCR | 16–32 | N87I | S | 16–64 | 109 STOP | 73 STOP | |
| MT2127 | HGCR | S | S | 64–128 | 38 STOP | |||
| MT2129* | HGCR | S | S | 64 | 51 STOP | 38 STOP | ||
| MT2130 | HGCR | S | S | 16–32 | 38 STOP | |||
| MT2131 | HGCR | S | S | 8–16 | 90 STOP | |||
| MT2133 | HGCR | 2–4 | D91G | S | 32–64 | 38 STOP | ||
| MT2136 | HGCR | S | N87T | S | 64–128 | 38 STOP | ||
| MT2156 | HGCR | S | S | 64 | 38 STOP | |||
| MT2160* | HGCR | 4–8 | D91Y | S | 64 | 29 STOP | 38 STOP | |
| PZ5056 | HGCR | S | 2 | A926G | 32–64 | 157 STOP | 19 STOP | |
| PZ5080 | HGCR | S | S | S | 73 STOP | |||
| PZ5086 | HGCR | S | S | 64–128 | 206 STOP | |||
| 26695 (ATCC 700392) | Reference strain | |||||||
| ATCC 43504 | Reference strain | 72 STOP | 38 STOP |
a
Phenotypically resistant MIC values (μg/ml) and drug resistance-associated mutations are highlighted in gray shading. Truncated and elongated rdxA and frxA genes are indicated by their length in amino acid residues and “STOP” or “ELONGATED,” respectively. LEV, levofloxacin; TET, tetracycline; MTZ, metronidazole.
b
Asterisk (*) indicate isolates evaluated by PCR and whole-genome sequencing (WGS).